Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Retained Earnings (2020 - 2025)

Historic Retained Earnings for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to -$94.0 million.

  • SAB Biotherapeutics' Retained Earnings rose 1663.61% to -$94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.0 million, marking a year-over-year increase of 1663.61%. This contributed to the annual value of -$124.2 million for FY2024, which is 3786.81% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Retained Earnings of -$94.0 million as of Q3 2025, which was up 1663.61% from -$139.5 million recorded in Q2 2025.
  • SAB Biotherapeutics' Retained Earnings' 5-year high stood at $3.0 million during Q1 2021, with a 5-year trough of -$139.5 million in Q2 2025.
  • Its 5-year average for Retained Earnings is -$66.1 million, with a median of -$62.1 million in 2023.
  • Its Retained Earnings has fluctuated over the past 5 years, first plummeted by 441973.26% in 2022, then soared by 1663.61% in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Retained Earnings (Quarter) stood at -$29.1 million in 2021, then tumbled by 64.34% to -$47.9 million in 2022, then plummeted by 88.14% to -$90.1 million in 2023, then crashed by 37.87% to -$124.2 million in 2024, then increased by 24.27% to -$94.0 million in 2025.
  • Its Retained Earnings was -$94.0 million in Q3 2025, compared to -$139.5 million in Q2 2025 and -$129.4 million in Q1 2025.